Dhanuka Agritech Ltd

Q4 FY26Fertilizers & Agrochemicals

Dhanuka Agritech Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹980

Market cap₹4.5K Cr

P/E16.7

Updated23 Aug 2026

Read5 min read

The short version

Company expects low double-digit growth in sales/revenue for FY '27. - Price growth is anticipated to be higher than volume growth, with volume growth lagging slightly. - Volume growth expected around 2% less than price growth. - Growth drivers include increased cotton, pulses, and oilseed acreages; soybean acreages are uncertain but could benefit from price increases. - Biostimulant portfolio expected to grow from Rs. Management expects low double-digit revenue growth for FY '27, driven by price growth outpacing volume growth by about 2%.

From Dhanuka Agritech Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Company expects low double-digit growth in sales/revenue for FY '27.
Price growth is anticipated to be higher than volume growth, with volume growth lagging slightly.
Volume growth expected around 2% less than price growth.
Growth drivers include increased cotton, pulses, and oilseed acreages; soybean acreages are uncertain but could benefit from price increases.
Biostimulant portfolio expected to grow from Rs. 110 crores in FY '25 to over Rs. 130 crores in FY '27.
Bayer product revenues expected to almost double in FY '27 compared to FY '26.
Dahej facility revenue guidance downgraded to Rs. 75 crores (from Rs. 100 crores) for FY '27 but still 50% growth over FY '26.
Strategic focus on robust weedicide portfolio and upcoming launch of three biostimulant products in June to support growth.

Profitability & Margins

Management expects low double-digit revenue growth for FY '27, driven by price growth outpacing volume growth by about 2%.
EBIT/EBITDA margins may see a slight 100 bps decline due to loss of GST refund and reduced economic benefits, but gross margins are expected to be broadly maintained.
Other income is expected to rise due to appreciation in investments (e.g., KisanKonnect), supporting profitability.
New product launches, especially in biostimulants and herbicide portfolios (e.g., soybean-focused products), are expected to contribute to growth.
The inclusion of Bayer product revenues will partially impact growth in FY '27, with full contribution expected in FY '28.
Operational efficiencies, cost management, and smart sourcing are expected to sustain profit growth despite inflationary pressures.
Overall, management remains confident about strong earnings growth supported by market expansion, product launches, and stable margins.

See what Dhanuka Agritech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

- The company is focusing on building future-ready capabilities across manufacturing, R&D, and market development to support its next growth phase. - No specific current or future capex figures or strategic investments were detailed in the provided transcript. - There is mention of continued engagement with agricultural universities and scientific institutions for farmer education and technology dissemination, indicating ongoing investments in knowledge partnerships. - The management refers to labor shortages linked to several CapEx initiatives by government and private sectors, implying some industry-wide investments but without specifying Dhanuka's direct capex plans. - Investments include new product launches, such as biostimulants and active molecule manufacturing in India (for one Bayer-acquired molecule), suggesting capital deployment in production facilities. - The company made investments in entities like KisanKonnect, contributing to other income via valuation appreciation. No explicit detailed capex budget or future strategic capex commitments were disclosed.

Top-ranked in Fertilizers & Agrochemicals

Ranked on what management guided this quarter

5x potential

1Anya Polytech &₹180 Cr

Rev 2Mar 1

2Dharmaj Crop Guard Ltd₹911 Cr

Rev 2Mar 2

3₹5.6K Cr

Rev 2Mar 3

4₹1.3K Cr

Rev 3Mar 1

5₹56.9K Cr

Rev 3Mar 3

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

No explicit mention of any current or future fundraising through debt or equity was made in the provided transcript.
The company has approved a buyback proposal of up to Rs. 70 crores at Rs. 1,400 per share, indicating strong confidence in cash flows and future growth, rather than raising capital.
An Employee Stock Option Plan (ESOP) has been introduced to enhance long-term alignment and support growth, but this is not a capital raise through issuance.
There is no discussion or indication of plans to raise funds via new debt or equity issuance in the Q&A or closing remarks.

See what Dhanuka Agritech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly mention the current or expected order book or pending orders for Dhanuka Agritech Limited. However, some relevant insights related to demand and inventory are: - Q4 placement was similar to previous years; no significant pre-placement in the market. - Availability of technical materials/imports is not a challenge; supply is secured for Kharif season. - Herbicide consumption has just started; demand is somewhat mixed between actual demand and channel pull. - Strong sales and growth expected in Dahej unit with a revenue forecast of Rs. 75 crores for FY ’27, up 50% from FY ’26. - Growth anticipated in biostimulants and biological products with new product launches in June and expected revenue over Rs. 130 crores. - Management optimistic about robust Q1 performance driven by rainfall and increasing oilseed and pulse acreages. No explicit figure or detailed order book data was provided in the available content.

Dhanuka Agritech Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹483 Cr, net profit ₹98 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Dhanuka Agritech Ltd's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season

Indogulf Cropsciences Ltd (Q4 FY26)
Successful single order in Venezuela contributing approximately INR 4 crores in revenue, indicating active export orders. Key concall takeaways from Indogulf…
Rallis India Ltd (Q4 FY26)
Crop Protection B2C business growth excluding Soil & Plant Health (SPH) will be marginally positive to low single digit; SPH segment grew robustly at 27%. Key…
Punjab Chemicals & Crop Protection Ltd (Q4 FY26)
Overall volume growth in FY '26 was around 14%, primarily driven by new products. Key concall takeaways from Punjab Chemicals & Crop Protection Ltd's Q4 FY26…
Krishana Phoschem Ltd (Q4 FY26)
The Company has recently completed a significant capacity expansion: NPK/DAP capacity increased by 50% to 495,000 MTPA, SSP capacity at 120,000 MTPA, totaling…

Compare:vs Coromandel International Ltd vs Fertilizers & Chemicals Travancore Ltd vs UPL Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Dhanuka Agritech Ltd Q4 FY26 results?

What is Dhanuka Agritech Ltd share price analysis?

Dhanuka Agritech Ltd currently shows a neutral. The stock trades at a P/E of 16.7 with a market cap of ₹4,482 Cr. Investors should review the full earnings analysis for detailed insights.

Is Dhanuka Agritech Ltd planning capital expenditure?

The company is focusing on building future-ready capabilities across manufacturing, R&D, and market development to support its next growth phase.

Keep Dhanuka Agritech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.